| JAK-STAT signaling |
149 |
08-nov-2026 |
|
| Inflammatory cytokine signaling |
53 |
01-nov-2026 |
|
| Thrombosis risk |
49 |
11-oct-2026 |
|
| Bone marrow fibrosis |
49 |
04-oct-2026 |
|
| CALR mutations |
45 |
25-oct-2026 |
|
| Clonal hematopoiesis |
43 |
01-nov-2026 |
|
| MPL mutations |
26 |
18-oct-2026 |
|
| Blast-phase MPN and leukemic transformation |
26 |
18-oct-2026 |
|
| DNA hypomethylation and epigenetic reprogramming |
23 |
13-sep-2026 |
|
| Interferon-α mechanism of action in MPN |
20 |
08-nov-2026 |
|
| ACVR1 signaling and hepcidin axis |
19 |
25-oct-2026 |
|
| Megakaryocyte dysfunction |
16 |
04-oct-2026 |
|
| TGF-β superfamily signaling in MPN |
13 |
25-oct-2026 |
|
| XPO1 nuclear export |
13 |
13-sep-2026 |
|
| ASXL1 mutations |
11 |
11-oct-2026 |
|
| TET2 mutations |
11 |
13-sep-2026 |
|
| LSD1 (KDM1A) inhibition |
9 |
20-sep-2026 |
|
| PD-1/PD-L1 immune checkpoint signaling in MPN |
9 |
13-sep-2026 |
|
| MPN clonal evolution trajectories to transformation |
8 |
11-oct-2026 |
|
| Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain |
7 |
27-sep-2026 |
|
| ERK/MAPK signaling in MPN |
6 |
04-oct-2026 |
|
| PI3K-AKT signaling |
6 |
04-oct-2026 |
|
| CCR2 monocyte trafficking in MPN fibrosis |
6 |
04-oct-2026 |
|
| Cytokine-induced memory-like (CIML) NK cells in myeloid malignancies |
5 |
13-sep-2026 |
|
| S100A9 alarmin signaling |
4 |
13-sep-2026 |
|
| m6A epitranscriptomic regulation in MPN |
1 |
18-oct-2026 |
|
| Erythrocyte rigidity and clot pathology in JAK2-MPN |
1 |
11-oct-2026 |
|
| Bone marrow macrophage microenvironment in CMML |
1 |
04-oct-2026 |
|
| PIM1 kinase signaling in MPN |
1 |
04-oct-2026 |
|
| TP53 mutations in MPN |
1 |
27-sep-2026 |
|
| Fibrocytes as collagen-producing drivers of BM fibrosis in MPN |
1 |
27-sep-2026 |
|
| TYK2 signaling dependency in CALR/MPL-mutant MPN |
1 |
27-sep-2026 |
|
| CSF1R macrophage/monocyte signaling in MPN |
1 |
13-sep-2026 |
|
| UTS (U2AF1/TP53/SRSF2) high-risk mutation signature in SMF |
1 |
13-sep-2026 |
|
| Therapy-associated mutagenesis in MPN |
1 |
13-sep-2026 |
|
| BCL-2/BCL-xL dual inhibition and apoptotic dependence in myeloid neoplasms |
1 |
13-sep-2026 |
|
| EZH2 mutations |
1 |
13-sep-2026 |
|
| Glutamate–mGluR5–fumarate metabolic rewiring of MSCs |
1 |
13-sep-2026 |
|
| DNMT3A mutations |
1 |
13-sep-2026 |
|
| Metabolic syndrome as a pathophysiological modifier in polycythemia vera |
1 |
13-sep-2026 |
|
| Oxidative stress in MPN |
1 |
13-sep-2026 |
|
| MF spleen spatial niche compartments (IV/PV/RP) |
1 |
13-sep-2026 |
|
| Ferroptosis in MPN and hematological malignancies |
1 |
13-sep-2026 |
|
| Oxidative stress, lipid peroxidation, and malondialdehyde (MDA) |
1 |
13-sep-2026 |
|
| Immune microenvironment dysregulation in MPN |
1 |
13-sep-2026 |
|
| NF-κB signaling in MPN |
1 |
13-sep-2026 |
|
| MDM2–p53 axis in MPN |
1 |
13-sep-2026 |
|
| Telomerase inhibition in MPN |
1 |
13-sep-2026 |
|
| PIM kinase signaling in MPN |
1 |
13-sep-2026 |
|
| BET bromodomain epigenetic regulation in MPN |
1 |
13-sep-2026 |
|
| Acquired von Willebrand syndrome in MPN |
1 |
13-sep-2026 |
|
| NK cell immune surveillance in MPN |
1 |
13-sep-2026 |
|
| Bone marrow mast-cell infiltration and pruritus in MPN |
1 |
13-sep-2026 |
|
| Cytopenic vs proliferative PMF phenotypes |
1 |
13-sep-2026 |
|
| Complement C3-driven stromal reprogramming in MPN |
1 |
13-sep-2026 |
|
| TPO/MPL signaling axis |
1 |
13-sep-2026 |
|
| Endothelial-to-mesenchymal transition in MPN cardiovascular disease |
1 |
13-sep-2026 |
|
| Thrombopoietin/MPL signaling in endocardial endothelium |
1 |
13-sep-2026 |
|
| Inducible caspase-9 (iCasp9) suicide gene T-cell elimination mechanism |
1 |
05-jul-2026 |
|
| DDX5 RNA helicase scaffolding co-activator in JAK2/MYC signaling |
1 |
05-jul-2026 |
|
| MPN-associated IgA nephropathy and IL-6/IL-11 mesangial axis |
1 |
05-jul-2026 |
|
| CD4-directed CAR-T cell therapy (CD4CAR) in CMML |
1 |
28-jun-2026 |
|
| Galectin-1 / TLR4 / NF-κB monocyte inflammation axis in MPN |
1 |
28-jun-2026 |
|
| Lysozyme-associated nephropathy mechanism |
1 |
21-jun-2026 |
|
| Type II JAK2 inhibition (inactive-conformation) |
1 |
14-jun-2026 |
|
| SLAMF7-directed immunotherapy in MPN |
1 |
14-jun-2026 |
|
| JAK2-driven vasculopathy and thoracic aortic aneurysm |
1 |
07-jun-2026 |
|
| Eltrombopag (TPO-R agonism) and selective TET2-mutant clone suppression |
1 |
07-jun-2026 |
|
| TMPRSS6 inhibition and hepcidin-mediated iron restriction in PV |
1 |
07-jun-2026 |
|
| BET bromodomain inhibition in MPN |
1 |
07-jun-2026 |
|
| CREB3L1 mRNA as lineage-associated biomarker in MPN |
1 |
07-jun-2026 |
|
| JAK2V617F-mutated hemogenic endothelium as cell of origin in PMF |
1 |
31-may-2026 |
|
| Mutant IDH1 and 2-hydroxyglutarate oncometabolite signaling |
1 |
24-may-2026 |
|
| JAK2V617F allele dosage and HSC transcriptional priming |
1 |
17-may-2026 |
|
| MPN-specific antigens and anti-MPN T cell receptors |
1 |
17-may-2026 |
|
| PLK1 (Polo-like kinase 1) signaling in MPN/CMML |
1 |
28-apr-2026 |
|
| CSF-1R signaling and macrophage axis in MPN |
1 |
28-apr-2026 |
|
| IRAK1/NF-κB signaling in MPN |
1 |
28-apr-2026 |
|
| RSK1 (Ribosomal S6 Kinase 1) signaling in myelofibrosis |
1 |
28-apr-2026 |
|
| FGFR1 rearrangement signaling |
1 |
28-apr-2026 |
|